This insider cluster is routine and non-informative. The EVP's sale is a standard exercise-and-cover pattern with no bearish signal. Monitor for any material news (e.g., FDA decision on aficamten, upcoming earnings) that could drive the stock, but this filing itself provides no trading edge.
Price Chart
Executive Summary
Two insiders at Cytokinetics sold a combined $339K in open-market sales over a week. The EVP of R&D exercised and immediately sold option shares, a classic tax-covering pattern, while a director made a small sale. At a $10.2B market cap, these sales represent ~0.003% of market cap — trivial and routine, not indicative of bearish conviction. The historical calibration shows prior bullish/neutral reports on CYTK have underperformed at T+20 (0% win rate), reinforcing that this filing carries no actionable signal.
Key Financial Metrics
Key Facts
- EVP R&D Malik Fady Ibraham exercised 3,500 options at $7.80/share and immediately sold 3,500 shares at $75.46 for $264K — a routine exercise-and-sell pattern to cover tax obligations.
- Director Robert E. Landry sold 1,000 shares at $74.66 for $75K — a very small position reduction.
- Total open-market sales of $339K represent ~0.003% of CYTK's $10.2B market cap — far below the 0.1% materiality threshold.
- No open-market purchases were made by any insider in this cluster.
Financial Impact
Total insider sales of $339K, or ~0.003% of market cap — immaterial.
Risk Factors
- Insider sales, while small, could be misinterpreted by retail as bearish.
- Cytokinetics is a binary-risk biotech — any negative regulatory or clinical news would overwhelm this trivial insider activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1789168927236 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access